Sijie Wang, Aktan Alpsoy, Surbhi Sood, Sandra Carolina Ordonez-Rubiano, Alisha Dhiman, Yixing Sun, Guanming Jiao, Casey J Krusemark, Emily C Dykhuizen
Chembiochem : a European journal of chemical biology 2021 Jul 01Polycomb group (PcG) proteins are epigenetic regulators that facilitate both embryonic development and cancer progression. PcG proteins form Polycomb repressive complexes 1 and 2 (PRC1 and PRC2). PRC2 trimethylates histone H3 lysine 27 (H3K27me3), a histone mark recognized by the N-terminal chromodomain (ChD) of the CBX subunit of canonical PRC1. There are five PcG CBX paralogs in humans. CBX2 in particular is upregulated in a variety of cancers, particularly in advanced prostate cancers. Using CBX2 inhibitors to understand and target CBX2 in prostate cancer is highly desirable; however, high structural similarity among the CBX ChDs has been challenging for developing selective CBX ChD inhibitors. Here, we utilize selections of focused DNA encoded libraries (DELs) for the discovery of a selective CBX2 chromodomain probe, SW2_152F. SW2_152F binds to CBX2 ChD with a Kd of 80 nM and displays 24-1000-fold selectivity for CBX2 ChD over other CBX paralogs in vitro. SW2_152F is cell permeable, selectively inhibits CBX2 chromatin binding in cells, and blocks neuroendocrine differentiation of prostate cancer cell lines in response to androgen deprivation. © 2021 Wiley-VCH GmbH.
Sijie Wang, Aktan Alpsoy, Surbhi Sood, Sandra Carolina Ordonez-Rubiano, Alisha Dhiman, Yixing Sun, Guanming Jiao, Casey J Krusemark, Emily C Dykhuizen. A Potent, Selective CBX2 Chromodomain Ligand and Its Cellular Activity During Prostate Cancer Neuroendocrine Differentiation. Chembiochem : a European journal of chemical biology. 2021 Jul 01;22(13):2335-2344
PMID: 33950564
View Full Text